Jinan Zhuocheng Bio-Tech Co., Ltd.

In 2026, China’s active pharmaceutical ingredient (API) industry is at a critical stage of transformation. On the one hand, China continues to play a significant role in the global pharmaceutical supply chain, supported by its well-established industrial ecosystem, large-scale manufacturing capacity and ongoing technological development. On the other hand, exchange rate fluctuations, intensifying international competition and changes in global supply chains are creating new challenges for exporters.

Against this backdrop, traditional export models based primarily on low costs and high sales volumes are becoming increasingly difficult to sustain. Chinese API manufacturers need to move beyond simply selling products overseas and develop a more comprehensive approach to internationalization. Optimizing product portfolios, diversifying target markets, strengthening local operations and improving risk management will be essential to building long-term competitiveness.

1. Optimizing Product Portfolios and Moving Toward Higher-Value Segments

For many years, bulk APIs, including vitamins, antibiotics and certain cardiovascular drug ingredients, have formed an important part of China’s pharmaceutical exports. Large-scale production and cost advantages have enabled Chinese manufacturers to establish strong positions in international markets. However, some product categories face increasing challenges from market commoditization, shrinking margins and limited pricing power.

As exchange rate movements and raw material price fluctuations place greater pressure on profitability, manufacturers need to optimize their product portfolios and expand into specialized APIs with higher technical barriers and greater added value.

Peptide APIs, complex pharmaceutical intermediates and other specialty APIs offer new opportunities for manufacturers with strong R&D capabilities and robust quality management systems. Meanwhile, traditional bulk APIs can also benefit from process optimization, greener manufacturing, improved quality standards and higher production efficiency.

Going forward, manufacturers will need to balance the development of specialty products with the upgrading of established product lines. The objective is to move beyond price-based competition and build stronger advantages in technology, product quality and supply reliability, supporting more stable and long-term customer relationships.

2. Strengthening Technological Innovation and End-to-End Capabilities

Technological innovation is becoming an increasingly important foundation for international expansion. Overseas customers evaluate suppliers not only on price and production capacity, but also on process development, quality consistency, regulatory compliance and long-term supply reliability.

To meet these expectations, API manufacturers need to continue investing in R&D and strengthening their capabilities across key intermediates, API manufacturing and, where applicable, formulation development and technical support. Process innovation can help improve manufacturing efficiency, control production costs and maintain consistent product quality.

For specialty API manufacturers, capabilities in areas such as chiral synthesis, complex molecule synthesis, fermentation optimization and advanced purification can provide meaningful competitive advantages. Companies with formulation development expertise may also create additional value through closer technical coordination between API production and finished dosage manufacturing.

The value of technological innovation extends beyond the development of new products. It also lies in establishing sustainable process advantages, reliable quality systems and effective technical support. As international customers place greater emphasis on supply chain resilience and product consistency, manufacturers with strong proprietary technologies will be better positioned to participate in deeper global pharmaceutical partnerships.

3. Diversifying International Markets and Reducing Regional Dependence

Europe and North America have long been important destinations for Chinese API exports. However, evolving regulatory requirements, efforts to localize pharmaceutical supply chains and uncertainty in the international trade environment have increased the risks associated with excessive dependence on a limited number of markets.

While consolidating their presence in established markets, manufacturers can explore opportunities in Southeast Asia, South Asia, the Middle East and other regions based on product characteristics, regulatory requirements and customer demand.

Market entry strategies should reflect differences in registration procedures, procurement practices, payment capacity and local industrial policies. Singapore, for example, may serve as a regional business base for companies seeking to develop partnerships and better understand Southeast Asian markets. In Indonesia, manufacturers need to assess local registration requirements, domestic manufacturing policies and potential partnership models. In Malaysia, product registration and applicable certification requirements should also be evaluated in advance.

Market diversification is not simply a matter of increasing the number of export destinations. It requires product portfolios, customer development strategies and compliance systems tailored to each target market. By broadening their geographic reach and building regional expertise, manufacturers can improve their ability to respond to changes in international trade and market conditions.

4. Advancing Localization: From Exporting Products to Building Global Operations

Traditional API exports generally follow a straightforward model: products are manufactured in China and sold overseas through trading channels. However, as international customers increasingly demand reliable supply, responsive regulatory support, technical assistance and customized services, product delivery alone may no longer be sufficient to meet all customer expectations.

A more integrated approach to internationalization is becoming increasingly important. This involves extending capabilities beyond product supply to include regulatory support, customer service, regional business partnerships and supply chain coordination, according to the needs of each target market.

At the initial stage, companies can test market demand through distributor partnerships, product registration and licensing arrangements. As business grows, they can gradually establish regional commercial teams, technical support functions and local warehousing or logistics partnerships. For markets with sufficient demand and long-term strategic importance, overseas manufacturing facilities or regional R&D centers may also be considered.

Localization does not need to happen all at once. It should progress in stages, guided by market demand, expected returns and regulatory requirements. By strengthening their local service capabilities, manufacturers can build closer customer relationships and gradually evolve from product suppliers into global pharmaceutical supply chain partners.

5. Strengthening Foreign Exchange Risk Management

Exchange rate fluctuations remain an important operational risk for API exporters. For companies that price products in US dollars and operate with relatively narrow margins, an appreciation of the Chinese yuan can reduce the RMB value of export revenues and affect the valuation of outstanding foreign currency receivables and other monetary assets.

Without appropriate risk management measures, exchange rate movements may erode profits even when overseas orders remain stable or continue to grow. Foreign exchange management should therefore become part of routine business planning rather than relying solely on predictions of future currency movements.

Depending on their business scale, payment cycles and foreign currency exposure, companies can consider compliant financial hedging instruments such as forward foreign exchange contracts and currency options. They should also coordinate pricing strategies, contract terms and payment arrangements. Where commercially feasible, businesses may evaluate RMB settlement or contractual mechanisms that address significant exchange rate movements and allocate risks between parties.

A systematic approach to foreign exchange risk management can improve financial planning and reduce the impact of currency volatility on export operations.

Conclusion

In 2026, the international development of China’s API industry is moving beyond a competitive model centered primarily on cost and production scale. Technological innovation, product quality, diversified market access and comprehensive service capabilities are becoming increasingly important to long-term success.

To remain competitive, manufacturers need to optimize their product portfolios, strengthen R&D and process innovation, diversify international markets, develop localized operations at an appropriate pace and establish effective risk management systems.

By combining product competitiveness with integrated global operating capabilities, Chinese API manufacturers can respond more effectively to changes in the international supply chain and build a stronger foundation for sustainable growth in global markets.